Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase1b/2 clinical trial of mupadolimab in combination with pembrolizumab in patients with HPV+ oropharyngeal cancers that have failed previous treatment with anti-PD-1 therapy and chemotherapy.

Next Previous
Trial Profile

Phase1b/2 clinical trial of mupadolimab in combination with pembrolizumab in patients with HPV+ oropharyngeal cancers that have failed previous treatment with anti-PD-1 therapy and chemotherapy.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mupadolimab (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Mar 2022 According to a Corvus Pharmaceuticals media release, initial data is anticipated to be presented in the second half of 2022.
  • 01 Nov 2021 According to a Corvus Pharmaceuticals media release, results are anticipated in 2022.
  • 22 Sep 2021 According to a Corvus Pharmaceuticals media release, data from this study has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting in November.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top